ARK Investment Management LLC Sells 45,555 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

ARK Investment Management LLC lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 26.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,865 shares of the company's stock after selling 45,555 shares during the period. ARK Investment Management LLC's holdings in Teva Pharmaceutical Industries were worth $2,232,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TEVA. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries in the first quarter worth approximately $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth $30,000. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at $48,000. Finally, Byrne Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $52,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 2.2 %

NYSE TEVA traded down $0.39 on Friday, reaching $17.11. The stock had a trading volume of 6,225,171 shares, compared to its average volume of 9,292,936. Teva Pharmaceutical Industries Limited has a 1 year low of $8.55 and a 1 year high of $19.31. The business has a 50 day moving average price of $17.94 and a 200 day moving average price of $17.12. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The company has a market capitalization of $19.38 billion, a price-to-earnings ratio of -20.13, a P/E/G ratio of 1.25 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.04. The firm had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.08 billion. Teva Pharmaceutical Industries had a positive return on equity of 41.43% and a negative net margin of 5.73%. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TEVA shares. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.